Semaglutide Weight Management and Cardiovascular Risk Reduction
PIONEER PLUS with oral semaglutide in people with type 2
diabetes was successfully completed in Q2 2023
PIONEER PLUS enrolled 1606 patients with T2D
Oral semaglutide 50 mg
R
Oral semaglutide 25 mg
1:1:1
Oral semaglutide 14 mg
•
Objective:
To compare the safety and efficacy of once daily oral semaglutide
25 mg and 50 mg with oral semaglutide 14 mg in people with T2D
Primary endpoint:
Change from baseline to week 52 in HbA1c
Secondary confirmatory endpoints:
Change from baseline to week 52 in body weight
Key Inclusion criteria:
68 weeks
5 weeks
follow-up
•
Type 2 diabetes
•
HbA1c 8.0-10.5%
T2D: Type 2 diabetes; R: Randomisation; BMI: body mass index; SGLT-2i: Sodium/glucose co-transporter-2 inhibitors
BMI ≥25 kg/m2
Stable dose of 1-3 OADs (metformin, SU, SGLT-2i or DPP-4i)View entire presentation